SFX by Ex Libris Inc.

Title:	In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
Source:	Blood [0006-4971] Keats, Jonathan yr:2003

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Bergsagel, P Leif L. "Molecular pathogenesis and a consequent classification of multiple myeloma." Journal of clinical oncology 23.26 (2005): 6333-8.
description	2.	Agnelli, L. "Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma." Haematologica (2006): 56-65.
description	3.	Neri, A. "Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma." British journal of haematology 136.4 (2007): 565-73.
description	4.	Ri, M. "Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1." Cancer Science 100.2 (2009): 341-348.
description	5.	Chng, W. "Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling." Cancer research 67.7 (2007): 2982-2989.
description	6.	Soverini, S. "Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation." Blood 102.5 (2003): 1588-94.
description	7.	Tassone, P. "Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?" European journal of cancer 42.11 (2006): 1530-8.
description	8.	Sáez, B. "Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses." Cancer genetics and cytogenetics (2006): 143-9.
description	9.	Hideshima, T. "Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets." Nature reviews. Cancer 7.157813700 (2007): 585-598.
description	10.	Keats, Jonathan J J. "Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma." Cancer cell 12.2 (2007): 131-44.
description	11.	Podar, K. "The malignant clone and the bone-marrow environment." Best Practice & Research Clinical Haematology 20.4 (2007): 597-612.
description	12.	Mitsiades, Kenneth C S. "Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment." Journal of cellular biochemistry 101.4 (2007): 950-968.
description	13.	Annunziata, Owen D. "Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma." Cancer cell 12.2 (2007): 115-30.
description	14.	Anderson, Kenneth C C. "Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions." Experimental hematology 35.4 (2007): 155-62.
description	15.	Fletcher, Jordan M. "De novo coiled-coil peptides as scaffolds for disrupting protein-protein interactions." Chemical science 9.39 (2018): 7656-7665.
description	16.	Pawlyn C, C. "Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations." Blood 125.5 (2015): 831-40.
description	17.	Sougnez, A. "Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy." Cancer cell 25.1 (2014): 91-101.
description	18.	Liu, B. "HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells." Cancer Letters 296.2 (2010): 233-40.
description	19.	Hanlon, Harries L. "Evaluation of 13q14 Status in Multiple Myeloma by Digital Single Nucleotide Polymorphism Technology." The journal of molecular diagnostics (2009).
description	20.	De Raeve, H R R. "The role of the bone marrow microenvironment in multiple myeloma." Histology and histopathology 20.4 (2005): 1227-50.